Severe cutaneous adverse reactions to drugs
- PMID: 28476287
- DOI: 10.1016/S0140-6736(16)30378-6
Severe cutaneous adverse reactions to drugs
Erratum in
-
Department of Error.Lancet. 2017 Oct 28;390(10106):1948. doi: 10.1016/S0140-6736(17)31656-2. Epub 2017 Jun 13. Lancet. 2017. PMID: 28622954 No abstract available.
Abstract
During the past decade, major advances have been made in the accurate diagnosis of severe cutaneous adverse reactions (SCARs) to drugs, management of their manifestations, and identification of their pathogenetic mechanisms and at-risk populations. Early recognition and diagnosis of SCARs are key in the identification of culprit drugs. SCARS are potentially life threatening, and associated with various clinical patterns and morbidity during the acute stage of Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reactions with eosinophilia and systemic symptoms, and acute generalised exanthematous pustulosis. Early drug withdrawal is mandatory in all SCARs. Physicians' knowledge is essential to the improvement of diagnosis and management, and in the limitation and prevention of long-term sequelae. This Seminar provides the tools to help physicians in their clinical approach and investigations of SCARs.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):757-763. doi: 10.1016/j.jaip.2017.02.013. Epub 2017 Mar 27. J Allergy Clin Immunol Pract. 2017. PMID: 28351788
-
Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.Clin Exp Allergy. 2020 Jan;50(1):61-73. doi: 10.1111/cea.13513. Epub 2019 Oct 28. Clin Exp Allergy. 2020. PMID: 31608511
-
Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).Med Clin North Am. 2021 Jul;105(4):577-597. doi: 10.1016/j.mcna.2021.04.001. Med Clin North Am. 2021. PMID: 34059239 Review.
-
Epidemiology of severe drug hypersensitivity.Semin Cutan Med Surg. 2014 Mar;33(1):2-9. doi: 10.12788/j.sder.0057. Semin Cutan Med Surg. 2014. PMID: 25037253 Review.
-
[Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].Recenti Prog Med. 2014 Oct;105(10):379-84. doi: 10.1701/1626.17670. Recenti Prog Med. 2014. PMID: 25282350 Italian.
Cited by
-
Probable drug-induced systemic reaction without blood eosinophilia and rash- utility of eosinophilic cationic protein for diagnosis.Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241271712. doi: 10.1177/03946320241271712. Int J Immunopathol Pharmacol. 2024. PMID: 39214525 Free PMC article. No abstract available.
-
The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions.World Allergy Organ J. 2024 Aug 5;17(8):100936. doi: 10.1016/j.waojou.2024.100936. eCollection 2024 Aug. World Allergy Organ J. 2024. PMID: 39211425 Free PMC article.
-
Topical imiquimod adverse event: Beyond the local skin reaction-A case report.SAGE Open Med Case Rep. 2024 Aug 19;12:2050313X241274916. doi: 10.1177/2050313X241274916. eCollection 2024. SAGE Open Med Case Rep. 2024. PMID: 39165296 Free PMC article.
-
Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions.JAMA. 2024 Sep 3;332(9):730-737. doi: 10.1001/jama.2024.11437. JAMA. 2024. PMID: 39115856
-
Antibiotic-induced severe cutaneous adverse reactions: a single-center retrospective study over ten years.Front Immunol. 2024 Jul 18;15:1415830. doi: 10.3389/fimmu.2024.1415830. eCollection 2024. Front Immunol. 2024. PMID: 39091503 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous